Skip to main content
Top
Published in: Infectious Diseases and Therapy 2/2014

Open Access 01-12-2014 | Original Research

Current Microbiology of Surgical Site Infections in Patients with Cancer: A Retrospective Review

Authors: Kenneth V. I. Rolston, Lior Nesher, Jeffrey T. Tarrand

Published in: Infectious Diseases and Therapy | Issue 2/2014

Login to get access

Abstract

Background

Patients with solid tumors frequently undergo surgical procedures and develop procedure-related infections. We sought to describe the current microbiologic spectrum of infections at various sites following common surgical procedures.

Methods

This was a retrospective review of microbiologic data between January 2011 and February 2012. The sites studied were those associated with breast cancer surgery, thoracotomy, craniotomy, percutaneous endoscopic gastrostomy (PEG) tube insertion, and abdominal/pelvic surgery. Only patients with solid tumors were included.

Results

A total of 368 surgical site infections (SSIs) were identified (68 breast cancer related; 91 thoracotomy related; 45 craniotomy related; 75 PEG-tube insertion related; and 89 abdominal/pelvic surgery related). Of these, 58% were monomicrobial and 42% were polymicrobial. Overall, 85% of the 215 monomicrobial infections were caused by Gram-positive organisms and 13% by Gram-negative bacilli (GNB). Staphylococcus aureus was the predominant pathogen in monomicrobial infections (150 of 215, 70%). Sixty (40%) of these staphylococcal isolates were methicillin resistant (MRSA), and 65% had a vancomycin minimal inhibitory concentration (MIC) ≥1.0 µg/ml. Pseudomonas aeruginosa was the predominant GNB pathogen (19 of 27, 70%). Staphylococci were also the predominant pathogens in polymicrobial infections, while P. aeruginosa and Escherichia coli were the predominant GNB. Overall, 35% of isolates from polymicrobial infections were GNB. Cephalosporins (e.g., cefazolin) or amoxicillin/clavulanate was used most often for surgical prophylaxis, and 47% of organisms from monomicrobial infections (MRSA, P. aeruginosa) were resistant to them. A similar resistance pattern was observed in polymicrobial infections.

Conclusion

Staphylococcus species were isolated most often from the sites studied. Polymicrobial infections (42%) and GNB monomicrobial infections (13%) were relatively frequent causes of SSIs. Many of these infections were caused by organisms that are resistant to agents commonly used for surgical prophylaxis. Additionally, 65% of staphylococcal isolates had a vancomycin MIC ≥1.0 µg/ml, suggesting the need for alternative therapeutic agents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw. 2012;10:1412–45. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw. 2012;10:1412–45.
2.
go back to reference Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806.PubMedCrossRef Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806.PubMedCrossRef
3.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.PubMedCrossRef
4.
go back to reference Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among Gram-negative bacilli at a cancer center. Chemotherapy. 1999;45:325–34.PubMedCrossRef Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among Gram-negative bacilli at a cancer center. Chemotherapy. 1999;45:325–34.PubMedCrossRef
5.
go back to reference Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246–52.PubMedCrossRef Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246–52.PubMedCrossRef
6.
7.
go back to reference Brahmbhatt RD, Huebner M, Scow JS, et al. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19:3205–11.PubMedCentralPubMedCrossRef Brahmbhatt RD, Huebner M, Scow JS, et al. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19:3205–11.PubMedCentralPubMedCrossRef
8.
go back to reference Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev. 2013;11:CD005571.PubMed Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev. 2013;11:CD005571.PubMed
9.
go back to reference Mahajan SN, Ariza-Heredia EJ, Rolston KV, et al. Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics. Ann Surg Oncol. 2014;21:513–9.PubMedCrossRef Mahajan SN, Ariza-Heredia EJ, Rolston KV, et al. Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics. Ann Surg Oncol. 2014;21:513–9.PubMedCrossRef
10.
go back to reference Walcott BP, Redjal N, Coumans JV. Infection following operations on the central nervous system: deconstructing the myth of the sterile field. Neurosurg Focus. 2012;33:E8.PubMedCrossRef Walcott BP, Redjal N, Coumans JV. Infection following operations on the central nervous system: deconstructing the myth of the sterile field. Neurosurg Focus. 2012;33:E8.PubMedCrossRef
11.
go back to reference Murray PR BE, Phaller A, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 9th ed. Washington: ASM; 2007. Murray PR BE, Phaller A, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 9th ed. Washington: ASM; 2007.
12.
go back to reference LaSala PR, Segal J, Han FS, Tarrand JJ, Han XY. First reported infections caused by three newly described genera in the family Xanthomonadaceae. J Clin Microbiol. 2007;45:641–4.PubMedCentralPubMedCrossRef LaSala PR, Segal J, Han FS, Tarrand JJ, Han XY. First reported infections caused by three newly described genera in the family Xanthomonadaceae. J Clin Microbiol. 2007;45:641–4.PubMedCentralPubMedCrossRef
13.
go back to reference CLS M100-S18M-aM-A. Performance standards for antimicrobial susceptibility testing: eighteen informational 305 supplement. Wayne: Clinical and Laboratory Standards Institute; 2008. CLS M100-S18M-aM-A. Performance standards for antimicrobial susceptibility testing: eighteen informational 305 supplement. Wayne: Clinical and Laboratory Standards Institute; 2008.
14.
go back to reference Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606–8.PubMedCrossRef Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606–8.PubMedCrossRef
15.
go back to reference Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;1999(20):250–78.CrossRef Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;1999(20):250–78.CrossRef
16.
go back to reference Avritscher EB, Cooksley CD, Rolston KV, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer. 2014;22:527–35.PubMedCrossRef Avritscher EB, Cooksley CD, Rolston KV, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer. 2014;22:527–35.PubMedCrossRef
17.
go back to reference Dominioni L, Imperatori A, Rotolo N, Rovera F. Risk factors for surgical infections. Surg Infect (Larchmt). 2006;7(Suppl 2):S9–12. Dominioni L, Imperatori A, Rotolo N, Rovera F. Risk factors for surgical infections. Surg Infect (Larchmt). 2006;7(Suppl 2):S9–12.
18.
go back to reference Korinek AM, Golmard JL, Elcheick A, et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155–62.PubMedCrossRef Korinek AM, Golmard JL, Elcheick A, et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155–62.PubMedCrossRef
19.
go back to reference Sturgis TM, Yancy W, Cole JC, Proctor DD, Minhas BS, Marcuard SP. Antibiotic prophylaxis in percutaneous endoscopic gastrostomy. Am J Gastroenterol. 1996;91:2301–4.PubMed Sturgis TM, Yancy W, Cole JC, Proctor DD, Minhas BS, Marcuard SP. Antibiotic prophylaxis in percutaneous endoscopic gastrostomy. Am J Gastroenterol. 1996;91:2301–4.PubMed
20.
go back to reference Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;1999(27):97–132.CrossRef Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;1999(27):97–132.CrossRef
21.
22.
go back to reference Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–402.PubMedCentralPubMedCrossRef Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–402.PubMedCentralPubMedCrossRef
23.
go back to reference Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist. 2012;17:1329–36.PubMedCentralPubMedCrossRef Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist. 2012;17:1329–36.PubMedCentralPubMedCrossRef
24.
go back to reference Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.PubMedCrossRef Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.PubMedCrossRef
25.
go back to reference Mukhtar RA, Throckmorton AD, Alvarado MD, et al. Bacteriologic features of surgical site infections following breast surgery. Am J Surg. 2009;198:529–31.PubMedCrossRef Mukhtar RA, Throckmorton AD, Alvarado MD, et al. Bacteriologic features of surgical site infections following breast surgery. Am J Surg. 2009;198:529–31.PubMedCrossRef
26.
go back to reference Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? Plast Reconstr Surg. 2010;126:779–85.PubMedCrossRef Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? Plast Reconstr Surg. 2010;126:779–85.PubMedCrossRef
27.
go back to reference Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.PubMedCrossRef Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.PubMedCrossRef
28.
go back to reference Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections: perioperative antimicrobial regimens. Infect Control Hosp Epidemiol. 2014;35:75–81.PubMedCrossRef Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections: perioperative antimicrobial regimens. Infect Control Hosp Epidemiol. 2014;35:75–81.PubMedCrossRef
Metadata
Title
Current Microbiology of Surgical Site Infections in Patients with Cancer: A Retrospective Review
Authors
Kenneth V. I. Rolston
Lior Nesher
Jeffrey T. Tarrand
Publication date
01-12-2014
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 2/2014
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-014-0048-4

Other articles of this Issue 2/2014

Infectious Diseases and Therapy 2/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.